The State of Tennessee, Department of Finance and Administration, Division of Benefits Administration (“State”) issues this Request for Information (“RFI”) for the purpose of soliciting information, recommendations, and potential solutions for driving appropriate prescribing and utilization of anti-obesity medications (AOMs), specifically GLP-1s, by Plan members. Solutions should support the State’s desire to offer members the most appropriate treatment, help relieve the financial impact of AOM coverage on the Plan, provide various methods of support to members, have proven clinical efficacy, and demonstrate a positive ROI. The State is interested in receiving information from companies with experience providing these services to large employers and whose providers are trained in obesity medicine. Given the current volume of rebates on these medications as well as the financial guarantees offered by the state’s current PBM, the State must consider any program’s impact on these variables in program ROI. The State, under authority of the State Insurance Committee, is conducting a study of these options. This market research is not a competition. No evaluation of participating vendors will occur, and your participation is not a promise of future business with the State. Responding or not responding to the RFI does not preclude the Vendor from submitting a proposal to any future solicitations/requests for proposals issued by the State. The State is NOT requesting specific pricing for any components or services addressed in this RFI. Instead, the State is seeking price ranges and structures for programs to determine, approximately, what these types of programs sought by the State will cost. Do NOT provide specific pricing amounts in response to this RFI. Should responses from this RFI generate additional questions from the State all vendors responding to this request will receive the additional questions and the State’s response.
